Biotheus' CD40 agonist is a ligand non-blocker and engineered so that they do not rely on Fc-mediated crosslinking for activation of CD40-expressing myeloid cells. This bispecific has been designed to activate CD40 on APCs via PD-1-mediated cross-bridging and cross-linking via antigen-specific T cells that closely interact with APCs. By testing CD40 bispecifics by paring with various T cell markers, PD-1 has been found to have most synergy as a binding pair. Thus, both PD-1 inhibition and CD40 agonism is contained within one molecule in PM1130. PM1130 may be used to treat multiple solid tumor types that could benefit from upregulating antigen presentation.